Pharma News
04 May 2025 to 10 May 2025
May 9, 2025
The market for generic medications is expected to grow to USD 594.99 million - GlobeNewswire
The global Generic Drugs Market is projected to grow from $423.55 billion in 2023 to $594.99 billion by 2031, driven by patent expirations and government initiatives promoting generics. Key players include Teva Pharmaceutical, Mylan, and Novartis. Notable drugs like Keytruda and Ozempic are set to lose patents, creating opportunities for affordable alternatives and reducing healthcare costs.
May 9, 2025
Pfizer's Stock Price Hits 13-Year Low: Is It a Good Time to Invest?
Pfizer (NYSE:PFE) shares have fallen to a 13-year low of $22.59, down 19% over the past year, primarily due to declining COVID-19 product sales and tariff uncertainties. Despite a robust oncology pipeline and a 7.5% dividend yield, risks remain, including competition and free cash flow challenges. Analysts rate PFE as a "Moderate Buy" with a target price of $29.
May 9, 2025
Cautions Regarding Budget and Medication Costs; Monitoring for Prostate Cancer; AI Achievements in Cancer Treatment
The American Association for Cancer Research urges Congress to reject the Trump administration's NIH budget proposal, advocating for increased funding. Meanwhile, AstraZeneca and Daiichi Sankyo report that trastuzumab deruxtecan (Enhertu) significantly outperforms chemotherapy in treating early HER2-positive breast cancer. Additionally, AI advancements show promise in cancer detection, while concerns arise over potential impacts of drug price negotiations on community oncologists.
May 9, 2025
Major Commitment: Essential Information on Weight Loss Medications | The Actuary
GLP-1 drugs, such as semaglutide (Ozempic, Wegovy) by Novo Nordisk and tirzepatide (Mounjaro, Zepbound) by Eli Lilly, are gaining recognition for treating obesity and improving metabolic health. With over half a million users in the UK, new formulations and generics are expected to enhance accessibility. However, challenges include side effects and the need for lifestyle changes to maintain weight loss.
May 8, 2025
Pfizer Files Lawsuit Against Alkem to Prevent Imitations of Xeljanz XR Arthritis Medication - Bloomberg Law
Pfizer Inc. has filed a federal lawsuit against Alkem Laboratories Ltd., claiming that the company's proposed generic versions of Xeljanz XR, specifically the 11- and 22-milligram tablets, infringe on its patent (US Patent No. RE41,783). Xeljanz, once a top-selling arthritis drug, saw US sales drop to $680 million in 2024 from $1.15 billion in 2023.
May 8, 2025
Trump set to reveal Medicare drug pricing strategy following hints of a "groundbreaking" announcement.
President Trump is set to announce a "most favored nation" plan aimed at reducing Medicare drug prices, previously attempted during his first term. The proposal ties high-cost Medicare drugs, like Ozempic, to the lowest prices in other countries. Trump's administration aims to negotiate costs with drug companies, despite past legal challenges and the Biden administration's abandonment of the initiative.
May 8, 2025
Lilly Prevails in Legal Dispute with Compounders as Judge Supports FDA: Tirzepatide is No Longer ...
A Texas judge ruled in favor of Eli Lilly in its legal battle over compounded versions of its GLP-1 drug, tirzepatide. Judge Mark Pittman upheld the FDA's declaration that tirzepatide is no longer in shortage, preventing pharmacies from producing altered versions. This decision follows ongoing disputes with the Outsourcing Facilities Association regarding compounding regulations.
May 8, 2025
TEVA Surpasses Q1 Earnings Expectations and Anticipates $700M in Cost Reductions by 2027, Shares Rise - TradingView
Teva Pharmaceutical Industries reported Q1 2025 adjusted earnings of 52 cents per share, surpassing estimates, while revenues of $3.89 billion fell short. Growth was driven by generics and branded drugs like Austedo and Ajovy. Teva raised its Austedo revenue guidance and expects $700 million in cost savings by 2027. Shares rose over 9% following the announcement.
May 8, 2025
Ribo Life, a company focused on RNA-based medications, aims to explore new funding opportunities - Bamboo Works.
Suzhou Ribo Life Science Co. Ltd. has filed for a Hong Kong IPO to fund its research on nucleotide drugs, including six siRNA candidates in clinical trials. The company has raised 1.8 billion yuan and has partnerships with Qilu Pharmaceutical and Boehringer Ingelheim. Ribo Life aims to advance treatments for thrombotic diseases, hyperlipidemia, and hepatitis.
May 8, 2025
Exploring the Legal Landscape of GLP-1 Litigation - Life Science Leader
The GLP-1 drug market, including semaglutide and tirzepatide, is facing significant litigation challenges, including patent disputes and trademark infringement claims. Brand-name manufacturers are suing compounding pharmacies over safety and trademark issues, while the FDA's drug shortage list complicates the landscape. Companies must adapt their legal strategies to navigate this evolving environment and protect their market positions.
May 7, 2025
Novo Nordisk Reports Q1 2025 Earnings - CNBC
Shares of Novo Nordisk surged nearly 7% after the company projected improved sales for its weight loss drug Wegovy, following the FDA's end of a drug shortage ruling that allowed compounded alternatives. Despite lower-than-expected first-quarter sales and a trimmed full-year growth forecast, CEO Lars Fruergaard Jørgensen expressed optimism about regaining market share. Wegovy sales rose 83% annually, reaching 17.36 billion Danish kroner.
May 7, 2025
Novo Nordisk's stock rises 5% as the company anticipates a decline in Wegovy sales from competitors in 2025.
Novo Nordisk's shares rose nearly 7% after the company projected improved sales for its weight loss drug Wegovy in the second half of the year, as competition from compounded alternatives diminishes. Despite lower-than-expected first-quarter sales and a revised growth forecast for 2025, CEO Lars Fruergaard Jørgensen expressed optimism about Wegovy's market recovery following FDA rulings.
May 7, 2025
Sandoz seeks to prevent Amgen's legal team from pursuing patent claims in ongoing intellectual property dispute - Lawyerly
Sandoz seeks to protect information revealed in preliminary discovery orders from Amgen's patent attorneys amid a dispute over generic versions of Amgen's bone disease drugs. Sandoz argues that if Amgen's attorneys access this material, they should be prohibited from pursuing future related patents.
May 7, 2025
US judge supports FDA's decision to take Lilly's weight loss medication off the shortage list.
A U.S. federal judge upheld the FDA's decision to remove Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, from the short supply list, limiting access to cheaper copies. The ruling impacts compounding pharmacies that had been producing these drugs. The judge also denied similar requests for Novo Nordisk's Ozempic and Wegovy.
May 7, 2025
Novo Nordisk lowers projections as sales of Ozempic and Wegovy are affected by US generic alternatives.
Novo Nordisk has reduced its full-year revenue and profit forecasts for its GLP-1 drugs, Wegovy and Ozempic, due to competition from unauthorized compounded versions in the US. Despite a 6.8% share price increase following FDA intervention, concerns over market dominance persist, especially with rival Eli Lilly's advancements. Novo is investing heavily to boost production and maintain its market leadership.
May 7, 2025
Zacks Analyst Blog Features Johnson & Johnson and AbbVie - TradingView
Zacks.com highlights a comparison between Johnson & Johnson (JNJ) and AbbVie (ABBV) regarding their growth prospects. JNJ faces challenges with the loss of exclusivity for Stelara and ongoing talc lawsuits, while AbbVie is positioned for growth with successful products like Skyrizi and Rinvoq. Both companies are expected to see revenue increases in 2025, but AbbVie shows stronger potential.
May 7, 2025
Novo Nordisk Sees Surge in Wegovy Sales - Baystreet.ca
Shares of Novo Nordisk (NYSE:NVO) rose 3.1% after the company reported improved sales expectations for its Wegovy weight loss drug, despite lower first-quarter sales. CEO Lars Fruergaard Jørgensen noted that the end of a drug shortage ruling by the FDA would boost sales as competition from compounded drugs diminishes. First-quarter net profit reached 29.03 billion Danish kroner.
May 7, 2025
The emergence of Wegovy and Zepbound imitations has generated a billion-dollar industry - TradingView
Novo Nordisk reported first-quarter earnings of 78.09 billion Danish kroner, driven by strong demand for its obesity drug Wegovy, despite increased competition from compounded alternatives. Sales of Wegovy rose 83% to 17.36 billion kroner, but fell short of forecasts. The company lowered its full-year sales growth outlook due to the impact of US compounders on its market share.
May 7, 2025
Novo Nordisk Shares Rise Following Strong Q1 Performance; Lowers FY25 Forecast - RTTNews
Novo Nordisk A/S shares rose 6% in Denmark and 7% in pre-market NYSE trading after reporting a 14% net profit increase to 29.034 billion kroner, driven by its weight loss drug Wegovy. However, the company revised its 2025 sales growth outlook down to 13-21% due to increased competition from compounded GLP-1 treatments in the US.
May 7, 2025
Is There Potential for Summit Therapeutics Stock to Increase Your Investment? - Yahoo Finance
Summit Therapeutics' stock has surged due to optimism surrounding its cancer drug, Ivonescimab, which is currently in multiple trials but not yet approved. The drug has outperformed Merck's Keytruda in trials for non-small cell lung cancer, raising hopes for significant revenue. However, concerns about trial diversity and the high market cap of $21 billion may challenge investor returns.
May 7, 2025
Novo Nordisk lowers its 2025 projections due to competition from generic versions affecting Wegovy sales, while reporting a stronger-than-expected profit for the first quarter.
Novo Nordisk's shares rose nearly 7% after the company projected improved sales for its weight loss drug Wegovy in the second half of the year, as competition from compounded alternatives diminishes. Despite lower-than-expected first-quarter sales and a revised growth forecast for 2025, CEO Lars Fruergaard Jørgensen expressed optimism about Wegovy's market recovery following FDA actions.
May 6, 2025
India's upcoming pharmaceutical transformation: Overcoming patent challenges to lead the $200 billion biosimilars industry.
India faces challenges in producing affordable biosimilars, crucial for treating chronic diseases, as many biologics go off-patent. Patent evergreening, particularly by companies like Roche and Merck, hinders progress. A report highlights India's potential to lead in biosimilars, with over 98 already approved. To capitalize, India must revise guidelines, curb evergreening, and boost domestic production for equitable healthcare.
May 6, 2025
Dermatology offshoot Dermavon submits IPO application, highlighting its vitiligo treatment as a key investment opportunity - Kr Asia
Dermavon Holdings, a subsidiary of China Medical System (CMS), is preparing for an IPO in Hong Kong, focusing on dermatology treatments, including the promising ruxolitinib cream for vitiligo. Despite not yet being approved in China, ruxolitinib has shown significant results globally. Dermavon aims to expand its portfolio while facing challenges in R&D and declining margins.
May 5, 2025
Federal Circuit Maintains FDA Suspension in MSN-Novartis Patent Dispute - Bloomberg Law News
A Federal Circuit court has ordered a Delaware district court to maintain its pause on the FDA's final approval of MSN Laboratories Pvt. Ltd.’s generic version of Novartis AG’s heart-disease drug, Entresto. MSN is appealing rulings that prevent the early launch of its copy, preserving Novartis’ market exclusivity until July.
